Hinoman’s Vegetable Whole-protein Ingredient Granted GRAS Status

Hinoman, Ltd., has been granted self-affirmed GRAS (Generally Recognized as Safe) status for its Mankai, a vegetable whole-protein ingredient with high nutritional value. The announcement was made during the Institute of Food Technologists (IFT) conference in Chicago, July 12-14.

The GRAS designation is for the use of Mankai in functional foods and beverages, and was confirmed based on scientific methods, as well as corroborated by extensive history of use in Asia Pacific. The status was endorsed by a third party-appointed panel composed of some of the top food toxicologists in the U.S. This approval clearly demonstrates Mankai’s preeminence in tests of food safety and purity.

The nutritional composition of the Mankai microgreen ingredient has been determined to be high in protein (at least 45-48%), low in fat (7-8%), with 24-45% carbohydrate content. Analysis of the amino acid composition reveals the protein to be a rich source of the entire group of essential amino acids.

“GRAS approval of the Mankai high-protein ingredient is a major step toward Hinoman becoming a key microgreen protein supplier in the U.S. market,” says Udi Alroy, VP of Marketing and Business Development for Hinoman. “Hinoman’s proprietary cultivation platform makes Mankai a reliable, sustainable food source for large-scale growth and consumption.”

Mankai is produced in an advanced hydroponic system that optimizes yield throughout the year. This precisely regulated aquaculture platform is highly controlled, operating under remote cultivation management and regulation. As a result, it ensures plant purity so that Mankai is clean and free from all pesticides and heavy metals, to a level that exceeds nutritional grade.

“The proprietary Hinoman technology enables strict standards of food safety and security, and both are critical to ensure a sustainable supply chain,” explains Ron Salpeter, CEO for Hinoman. “The system addresses the challenges of future agriculture and nutrition needs with simplicity and sustainability, providing a comprehensive, plant-derived whole-protein food solution.”

Algatechnologies Invests $20 million in Natural Astaxanthin Production

Algatechnologies (“Algatech”), Israel, announces a more than 100% expansion of its production capacity of AstaPure® brand natural astaxanthin. This doubling of capacity follows an investment of $20 million in its state-of-the-art facility in the Arava Desert, Israel.

This significant step is only part of the transformation by Algatech’ new owners, Grovepoint, since the UK investment group acquired control of Algatech in 2013. Grovepoint’s distinct aim is development and capitalization of the potential business in natural astaxanthin and related products.

“The expansion will be executed in phases, with a substantial part to be completed in 2014,” says Hagai Stadler, CEO of Algatech. “Part of the new plant is dedicated specifically for production of new microalgae products, based on our expertise and capabilities in the microalgae cultivation process. Innovative technologies will be merged into the current process to increase the facility yield and to reduce costs”

The past few years have witnessed dramatic growth in awareness of the health benefits of natural astaxanthin. This stems from the publication of a number of important clinical trials showing that regular consumption of astaxanthin helps protect the body from health disorders related to oxidative stress.

“This expansion of the production of astaxanthin from microalgae will allow Algatech to maintain its significant leadership position in existing markets as well as leverage it to develop new ones,” adds Leon Blitz, Grovepoint leading director.

The AstaPure® brand is sold mainly in North America, Europe and Asia as an active ingredient in dietary supplements, cosmetics and functional foods and beverages.

“The expansion is symbol of trust on the future of the natural astaxanthin, and in it growth in the coming years” says Ed Hofland, Algatech Chairman.

Related articles